|
|
 |
|
| Description |
| The CD44 antibody (clone DB105) recognizes the CD44 antigen. CD44 is a marker for many types of cancer stem cells (CSC), including breast CSCs that possess higher tumorigenicity and metastatic potential1, colorectal2, pancreatic3, and prostate4,5 CSCs. In addition, expression was observed in several cancers as well as on carcinoma cell lines. Here, it plays a role in cancer cell migration and matrix adhesion in response to a cellular microenvironment, thus enhancing cellular aggregation and tumor cell growth6. CD44 is also expressed on mesodermal cells, such as hematopoietic, fibroblastic, and glial cells. |
| Applications |
| CD44 antibodies can be used for the identification or enumeration of CD44+ cells by flow cytometry or fluorescence microscopy. |
| Clone | Isotype |
| DB105 | Mouse IgG1 |
| |
| Figure 1 |
| Cells from U937 (CD44+) and 1881 (CD44–) cell lines were combined and fluorescently stained with CD44-FITC, CD44-PE, CD44-APC and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. |
 |
 |
 |
|
|
|
|
| My favorites |
| Your current favorite list is empty. |
|
| Products |
| CD44-FITC, human |
- for 100 tests (1)
Download datasheet
130-095-195
|
| CD44-PE, human |
- for 100 tests (1)
Download datasheet
130-095-180
|
| CD44-APC, human |
- for 100 tests (1)
Download datasheet
130-095-177
|
| (1) One test corresponds to fluorescent labeling of up to 107 cells in a total volume of 100 μL. |
|
| References |
| 1. Al-Hajj, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100: 3983–3988. |
| 2. Dalerba, P. et al. (2007) Proc. Natl. Acad. Sci. USA 104: 10158–10163. |
| 3. Li, C. P. et al. (2007) Cancer Res. 67: 1030–1037. |
| 4. Patrawala, L. et al. (2006) Oncogene 25: 1696–1708. |
| 5. Collins, A. T. et al. (2005) Cancer Res. 65: 10946–10951. |
| 6. Aruffo, A. et al. (1990 Cell 61: 1303–1313. |
|
|
|
© 1999 - 2010 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
